COMMUNIQUÉS West-GlobeNewswire

Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
19/10/2026
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 U.S. net revenue grows 29% sequentially, driving third quarter global [...]
Nyxoah Annonce ses Résultats Préliminaires pour le Troisième Trimestre 2026 et Ajuste ses Prévisions de Chiffre d’Affaires pour 2026
19/10/2026
INFORMATIONS RÉGLEMENTÉES INFORMATIONS PRIVILÉGIÉES Nyxoah Annonce ses Résultats Préliminaires pour le Troisième Trimestre 2026 et Ajuste ses Prévisions de Chiffre d’Affaires pour 2026 Le chiffre d’affaires net aux [...]
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
19/10/2026
NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage [...]
GuideAI Health Enters Clinical Study and Software Pilot Agreement with Boone Heart Institute
19/10/2026
Collaboration aims to evaluate AI-assisted lower extremity CT angiography and pilot GuideAI's Elevate platform in a preventive cardiology setting BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (Cboe CA: [...]
Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology
19/10/2026
Company Continues to Advance Global Regulatory Strategy While Supporting U.S. Commercial Expansion NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or [...]
SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
19/10/2026
Groundbreaking 4-year safety and efficacy results: 37% reduction in mean intraocular pressure (IOP) across all dose groups 86% of patients remained off all topical IOP-lowering drops 90% of patients maintained ≥20/25 [...]
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
19/10/2026
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, announced [...]
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
19/10/2026
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors
19/10/2026
Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( [...]
Leads Biolabs' Opamtistomig and LBL-034 Featured in Six Abstracts at 2026 ESMO Congress
19/10/2026
Three Studies Selected for Oral Presentation, Including a Late-Breaking Abstract; Data Highlight Durable Responses and Long-Term Survival Signals Across Immunologically Cold Tumors and Deep, Sustained Responses in [...]
FOXO TECHNOLOGIES INC.’S SUBSIDIARY, MYRTLE RECOVERY CENTERS, INC., ANNOUNCES EXPANSION OF ITS FLAGSHIP FACILITY AND FOCUS ON SUBSTANCE USE DISORDER PATIENTS WITH RELATED MEDICAL CARE NEEDS
19/10/2026
WEST PALM BEACH, FL, Oct. 19, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc.’s (OTC: FOXO) (“FOXO”) is pleased to announce that its subsidiary, Myrtle Recovery Centers, Inc. (“Myrtle”), recently received its license [...]
Phase 3 trial in China successfully confirms ACARIZAX® safety and efficacy in patients with house dust mite allergy
19/10/2026
Inside Information Phase 3 trial with ACARIZAX ® in Chinese participants met the primary objective and showed efficacy in line with previous trials, after only 24-28 weeks of treatment. ACARIZAX ® was shown to be safe [...]
Standard Dental Labs Signs $10 Million Equity Purchase Agreement with Twenty Four Capital
19/10/2026
Facility gives the Company discretion to access equity capital over time to support its Florida dental laboratory strategy ORLANDO, Fla., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (OTCQB: TUTH) (“SDL” [...]
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
19/10/2026
SUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
19/10/2026
Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows MENLO PARK, Calif. and DALLAS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB [...]
23andMe Research Institute to Showcase Scientific Impact and Expanded Research Capabilities at ASHG 2026
19/10/2026
New research and capabilities highlight the power of more than 11 million consented research participants PALO ALTO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- At the American Society of Human Genetics (ASHG) 2026 Annual [...]
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
19/10/2026
Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival. Exploratory Subgroup analysis reveals [...]
TerrAscend to Host Third Quarter 2026 Earnings Conference Call
19/10/2026
TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today announced that it will host a scheduled conference call to [...]
Final Safety, Pharmacokinetic and Pharmacodynamic Data from COL-5671 Phase 1 Clinical Study Presented at UEGW
19/10/2026
COL-5671, a highly selective oral SIK3 inhibitor, demonstrated a favorable safety and pharmacokinetic (PK) profile Pharmacodynamic (PD) data indicate potent TNFα suppression at low doses , with even greater IL-23 [...]

Pages